首页
>
期刊首页
>
中医杂志(英文版)
>
2026年4期
>
Effect of Jinlong capsule(金龙胶囊)on the survival of patients with hepatocellular carcinoma:a propensity score matching study
Effect of Jinlong capsule(金龙胶囊)on the survival of patients with hepatocellular carcinoma:a propensity score matching study
摘要
OBJECTIVE:To evaluate the impact of Jinlong capsule(金龙胶囊)on the overall survival(OS)rates of patients with hepatocellular carcinoma(HCC)at various stages of the disease.
METHODS:A total of 799 patients diagnosed with HCC between January 2016 and December 2019 were enrolled.The three-year OS rate of the Jinlong group(n=144)was compared with that of the control group(n=655).To minimize potential bias,propensity score matching(PSM)was applied.Kaplan-Meier survival analysis was used to assess the OS rates of different subgroups,with statistical significance determined by the log-rank test.
RESULTS:The Cox regression model revealed that Jinlong treatment was independently associated with an improved three-year OS.The Jinlong group had a significantly higher OS rate than the control group,with an adjusted hazard ratio of 0.48(95%confidence interval:0.38-0.60;P<0.001).After applying PSM at a 1∶2 ratio,140 patients were included in the Jinlong group and 280 in the control group.The OS rate for the Jinlong group was substantially longer than that for the control group(65.7%vs 48.2%,P<0.0001).Additionally,the aHR for Jinlong use showed a dose-response effect:0.36 for 3-12 months,0.28 for 12-24 months,and 0.09 for>24 months of use.Compared to the control treatment,Jinlong treatment consistently reduced the risk of death within three years,of most subgroups.
CONCLUSIONS:Jinlong treatment significantly improved the three-year survival rate of patients with HCC.These findings provide a foundation for further studies into the effectiveness of Jinlong capsule in the treatment of HCC.
年,卷(期):
2026, 46(4)
机标分类号:
R726.9
R2
G252
在线出版日期:
2026年10月19日